Proscia launches Concentriq Embeddings, AI Toolkit
Oct. 2, 2024—Proscia announced the launch of Concentriq Embeddings and Proscia AI Toolkit.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
QIAstat-Dx instruments, assays get IVDR certification
Oct. 1, 2024—Qiagen announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE marking under the European Union in vitro diagnostic medical devices regulation.
Trial shows MeMed BV reduces use of unnecessary antibiotics
Sept. 30, 2024—MeMed announced the completion of its first randomized controlled trial to evaluate the MeMed BV test in the United States.
Unity Next Peer QC offered with Sysmex hemostasis systems
Sept. 23, 2024—Bio-Rad Laboratories has announced a partnership with Sysmex America in Bio-Rad’s Unity Next Peer QC software is now available with Sysmex CA-Series and CS-Series hemostasis systems for the United States.
Kisqali OK’d in people with HR+/HER2- early breast cancer
Sept. 20, 2024—Novartis announced FDA approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of people with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease.
Pathology Visions 2024—Decision Digital
Sept. 18, 2024—The Digital Pathology Association (DPA) invites you to attend this year’s annual meeting, taking place Nov. 3–5 in Orlando, Fla.
Qiagen calls for increased TB testing in the U.S.
Sept. 17, 2024—Qiagen is calling for a sharper focus on testing strategies to stop new cases of tuberculosis from further increasing and spreading in the United States.
Randox now offers Olink panels
Sept. 11, 2024—Randox now offers Olink dual-antibody recognition and proximity extension assay (PEA) technology, bringing the Olink Explore, Target, and Flex panels in-house to accelerate highly specific multiplex biomarker screening.
Pillar, AstraZeneca to expand access to liquid biopsy testing
Sept. 10, 2024—Pillar Biosciences has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing using rapid next generation sequencing–based liquid biopsy tumor profiling panels for detecting genetic cancer variants.
Vitros syphilis assay gets 510(k) clearance
Sept. 4, 2024—QuidelOrtho has received FDA 510(k) clearance for its Vitros syphilis assay, intended for the qualitative determination of total (IgG and IgM) antibodies to Treponema pallidum-specific antigens in human serum and plasma using the automated Vitros 3600, 5600, and XT 7600 systems.